ANDREA FONTANEZ: Open Payments
NPI 1124721667 · BEL AIR, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$843 in 52 payments from 14 companies in 2025. Trend: 2023 $70 · 2024 $786 · 2025 $843
Food & beverage: $843
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $280 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $93 |
| PFIZER INC. | 5 | $86 |
| Baxter Healthcare | 3 | $67 |
| Novo Nordisk Inc | 3 | $65 |
| Otsuka America Pharmaceutical, Inc. | 3 | $49 |
| Exact Sciences Corporation | 2 | $49 |
| AstraZeneca Pharmaceuticals LP | 2 | $37 |
| Axsome Therapeutics, Inc. | 1 | $27 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $23 |
Products named: VRAYLAR, CAPLYTA, NURTEC ODT, REXULTI, UBRELVY, Ozempic, Hillrom - Cardiac Ambulatory Monitor, BREZTRI.
Industry payments across MD — which companies pay providers there.
